PARPi have been observed to impact antitumor immune responses through different mechanisms, including activation of cGAS/STING and induction of immune response through DNA damage and genome instability.[11] Combined inhibition of PARP and checkpoint kinase 1 (CHK1) has also demonstrated enhanced antitumor effects in immune checkpoint blockade therapy (ICB) and increased cytotoxic T‐cell infiltration.[12] Combined treatment of PARPi and immunotherapy blockades is a growing potential approach to the treatment of patients with BRCA1/2‐mutant cancer.[13, 14]. The gene discussed is CGAS; the disease is cancer.